Tsumura & Co. (Tsumura) is a pharmaceutical company that manufactures and markets medicines derived from crude drugs obtained from plants and other natural sources. It is the clear leader in Japan’s prescription Kampo formulations, holding more than 80% of the domestic market. Operating within a single reportable business segment, Tsumura specializes in Kampo medicines and related traditional Chinese medicines, maintaining a strong footprint in Japan and an expanding operational base in China.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on developing new products and technologies in Japan and overseas. It also emphasizes research into cultivation techniques to secure stable supplies of crude drug raw materials, enhance crude drug quality, and strengthen Kampo product quality control and manufacturing technologies. The company plans to introduce upland ginseng cultivation and expand clinical facilities in the US. It operates a central research laboratory in Ibaraki, Japan. Tsumura’s R&D units include the Tsumura Kampo Research Laboratories, which conduct basic and clinical research to promote the standardization of Kampo treatment, focusing on geriatric health, cancer, women’s health, and cardiovascular health; the Tsumura Advanced Technology Research Laboratories, which pursue R&D using KAMPOmics, including pre-symptomatic disease R&D, personalized medicine R&D, systems biology research, and Kampo data science; and the CMC Development Research Laboratories, which are responsible for improving and developing manufacturing and quality control technologies, including formulation research, quality research, and quality assurance. Tsumura holds patents for new analytical technologies used in quality testing and quality control for exogenous impurities, including specific patents for analytical methods related to agrochemical residues in Japan, the United States, and China. In FY2026, the company reported research and development expenses of JPY8,484 million which amounted to 4.4% of the company’s total revenue and grew 1.5% YoY.